Very interesting site but the statement that is the killer for me against its main (to be read atm, only) rival Oralalert is most definitely the following-:
"Detects recent marijuana use at 4 ng/mL and impairment from marijuana at levels as low as 5 mg/mL has been demonstrated. This appropriate sensitivity allows relevant detection levels and the avoidance of problems associated with impairment, rather than relying solely on a strategy of deterrence"
Summary:
Oralalert- strategy of deterrence only -limited by sensitivity levels
Oralaline- strategy of both deterrence and impairment - best sensitivty levels in the world
The primary task of SBN management now is to get clearly the best product of its kind known to the widest global market possible (not to be compared to Cozart products because they target largely a different market segment ie high cost end). Remembering that SBN has had to start from scratch, it would seem given the 300% increase in sales over the last two quarters that they are certainly on their way.
The commercial equation often used for assessing technology companies is:
Premium Value = IP + IP generated sales
ciao
SBN Price at posting:
0.0¢ Sentiment: ST Buy Disclosure: Held
